Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Show more

Location: 3027 Townsgate Road, Westlake Village, CA, 91361, United States | Website: https://www.arcutis.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.062B

52 Wk Range

$8.90 - $27.08

Previous Close

$22.86

Open

$22.28

Volume

3,954,003

Day Range

$22.26 - $25.20

Enterprise Value

2.994B

Cash

191.1M

Avg Qtr Burn

-8.14M

Insider Ownership

1.74%

Institutional Own.

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZORYVE® (Roflumilast foam 0.3%) Details Skin disease/disorder, Seborrheic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Skin disease/disorder, Psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (roflumilast) Topical Foam 0.3% Details Plaque Psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic Dermatitis (Ages 2 to 5)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream 0.05% Details Atopic dermatitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-234 Details Moderate to severe atopic dermatitis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAKi) Details Vitiligo	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-255 topical ivarmacitinib Details Alopecia areata	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.